新型前列环素类似物MRE-269治疗老年大鼠卒中后持续神经功能恢复
该研究在老年雄性Sprague-Dawley大鼠短暂大脑中动脉闭塞模型中,于缺血后4.5小时静脉给予MRE-269(0.25 mg/kg)或溶媒,发现MRE-269可显著减小48小时和3周的梗死体积,并促进运动与感觉功能的长期恢复,同时减轻炎症、氧化应激和血脑屏障损伤。
要点
- 老年大鼠脑缺血后4.5小时静脉给予MRE-269可减小48小时和3周梗死体积。
- MRE-269治疗促进卒中后3至21天的运动与感觉功能长期恢复。
- MRE-269减轻缺血脑组织炎症、氧化应激及血脑屏障损伤。
核心结论
- 靶向IP受体(前列环素I2受体)的MRE-269可减轻脑缺血损伤并促进缺血性卒中后长期神经功能恢复。
研究设计与样本
- 老年雄性Sprague-Dawley大鼠行短暂大脑中动脉闭塞,随机接受溶媒或MRE-269(0.25 mg/kg)静脉注射,起始于缺血后4.5小时。
- 行为学测试(加速转棒和粘附物移除)在卒中前及卒中后3、7、14、21天进行。
- 梗死体积通过磁共振成像在MCAO后48小时和21天定量。
- 平行实验在MCAO后18小时收集卒中侧和非卒中侧大脑皮层样本进行分子生物学分析。
主要发现
- 定量MRI显示,与溶媒组相比,缺血后MRE-269治疗在卒中后48小时和3周均显著减小梗死体积。
- MRE-269治疗导致MCAO后运动和感觉功能的显著长期恢复,并与接受IP受体激动剂的动物体重减轻减少相关。
- 缺血后MRE-269治疗减少促炎细胞因子/趋化因子和氧化应激。
- MRE-269显著减少血脑屏障损伤(以免疫球蛋白G外渗至缺血脑组织评估),并与缺血后4.5小时给予IP激动剂的老年卒中大鼠脑内基质金属蛋白酶-9活性降低相关。
临床怎么用
- 提示靶向IP受体可能是减轻脑缺血损伤和促进缺血性卒中后长期神经功能恢复的新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Targeting the prostaglandin I2 prostanoid (IP) receptor to reduce stroke injury has been hindered by the lack of selective drugs. MRE-269 is the active metabolite of selexipag showing a high selectivity toward the IP receptor. Selexipag has been recently approved for clinical use in pulmonary hypertension. We hypothesized that postischemic treatment with MRE-269 provides long-lasting neuroprotection with improved neurological outcomes in a clinically relevant rat stroke model. METHODS: Aged male Sprague-Dawley rats underwent transient middle cerebral artery occlusion and were randomly selected to receive either vehicle or MRE-269 (0.25 mg/kg) intravenously starting at 4.5 hours post ischemia. Accelerating rotarod and adhesive removal tests were conducted before and at 3, 7, 14, and 21 days after stroke. Infarct volume was quantified by magnetic resonance imaging at 48 hours and 21 days post middle cerebral artery occlusion. In parallel experiments, cerebral cortex samples from stroke and nonstroke sides from vehicle- and MRE-269-treated groups were collected at 18 hours post middle cerebral artery occlusion for molecular biology analyses. RESULTS: Quantitative magnetic resonance imaging data showed that postischemic MRE-269 treatment significantly reduced infarct volume compared with vehicle-treated rats at both 48 hours and 3 weeks after stroke. MRE-269 treatment resulted in a significant long-term recovery in both locomotor and somatosensory functions after middle cerebral artery occlusion, which was associated with a reduced weight loss in animals receiving the IP receptor agonist. Postischemic MRE-269 treatment reduced proinflammatory cytokines/chemokines and oxidative stress. Damage to the blood-brain barrier, as assessed by extravasation of immunoglobulin G to the ischemic brain, was significantly reduced by MRE-269, which was associated with a reduction in matrix metalloproteinase-9 activity in the brain of stroked aged rats given the IP agonist at 4.5 hours after ischemia onset. CONCLUSIONS: Our data suggest that targeting the IP receptor with MRE-269 is a novel strategy to reduce cerebral ischemia injury and promote long-term neurological recovery in ischemic stroke.
引用
- Yang C, DeMars KM, Alexander JC, et al. Sustained Neurological Recovery After Stroke in Aged Rats Treated With a Novel Prostacyclin Analog. Stroke. 2017. PMID: 28588054. doi:10.1161/STROKEAHA.117.016474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。